Gordon Ramsay Declines Requests for Ozempic-Inspired Restaurant Menus
LONDON – Celebrity chef Gordon Ramsay has reportedly refused requests to develop menus catering to individuals using Ozempic and other weight-loss drugs, stating he doesn’t want his restaurants associated with the trend. Ramsay’s stance comes as the use of medications like Ozempic-originally intended for diabetes management-for weight loss continues to rise in popularity,prompting debate about the culinary industry’s role in accommodating the altered appetites of users.
The “Kitchen Nightmares” star recently launched his fine dining restaurant Bonheur in London’s Mayfair district,overseen by Chef Matt Abé. While discussing the new venture with The Sunday Times,Ramsay revealed he’s actively discouraging a growing number of requests for specialized menus designed for those experiencing reduced hunger due to Ozempic and similar drugs. “I don’t want to be associated with that,” Ramsay told the publication,adding that he doesn’t want to “cater to that.”
Ramsay’s comments reflect a broader discussion within the food and beverage industry regarding the potential impact of these medications on dining experiences.Ozempic and similar drugs work by slowing gastric emptying and suppressing appetite,leading to significantly reduced food intake. This has prompted some restaurants to consider offering smaller portion sizes or altered menus to appeal to this growing customer base.
Though,ramsay’s position suggests a reluctance to normalize or encourage the use of these drugs,or to fundamentally alter his culinary approach to accommodate them. He has built his reputation on delivering robust, flavorful dining experiences, and appears determined to maintain that standard regardless of current health trends. The chef’s decision underscores a potential divide within the industry between adapting to changing consumer needs and upholding established culinary principles.
